Cantor Fitzgerald upgraded Denali Therapeutics (DNLI) to Overweight from Neutral.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics Begins BLA Submission for Tividenofusp Alfa
- Denali initiates BLA filing for accelerated approval of tividenofusp alfa
- Denali Therapeutics price target lowered to $28 from $30 at BofA
- Denali Therapeutics assumed with an Overweight at Morgan Stanley
- Denali Therapeutics: Promising Growth Prospects Despite Recent Setbacks